Myelodysplastic Syndrome and AML Associated With PARP Inhibitors
Over the past 7 years, four PARP (poly[ADP-ribose] polymerase) inhibitors, niraparib, olaparib, rucaparib, and talazoparib, have been approved in the United States and have led to clinically significant improvements in progression-free survival in patients with recurrent or primary ovarian cancer. However, recent data has come to light that warns of potentially serious adverse events associated with this class of medications. Read more.
Net Spending on Specialty Pharmaceuticals Surging
Specialty pharmaceuticals are one of the fastest growing classes of medications in part due to rapidly rising drug prices, increased approval of biological agents, and medications that require specialized handling or administration techniques, and a focus on costly drugs to treat orphan conditions and/or complex conditions. Read more.